Selection of a high-level physician may help improve outcomes of nasopharyngeal carcinoma.

Intensity-modulated radiation therapy Interactive Risk Attributable Program Nasopharyngeal carcinoma Physician level Prognosis Propensity score matching

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2020
Historique:
received: 05 09 2019
revised: 10 12 2019
accepted: 24 03 2020
pubmed: 16 4 2020
medline: 15 4 2021
entrez: 16 4 2020
Statut: ppublish

Résumé

To assess the relationship between the level of clinical radiation oncologist and the prognosis of patients with nasopharyngeal carcinoma (NPC). To our knowledge, no previous study has explicitly assessed the relationship with cancer prognosis and clinical radiation oncologists level. The effect of physicians on the prognosis has been entirely ignored. Clinical data were collected for 1140 patients with newly diagnosed NPC. Based on the 3-year overall survival, the treating physicians were classified into 3 grades: high-level group, medium-level group, and low-level group. Cox proportional hazards regression analysis was used to assess the independent significance of different prognostic factors. Propensity score matching (PSM) was used to minimize the influence of confounders so that difference in outcomes provides an unbiased estimate of the influence of physician. Interactive Risk Attributable Program (IRAP) was used to calculate the attribution risk of individual risk factors or a combination of multiple factors. The 3-year OS in the high-level, medium-level, and low-level groups was 92.9%, 87.7%, and 83.5%, respectively (p = 0.003). After propensity score matching, the 3-year OS was 92.4%, 87.4%, and 82.9%, respectively (p = 0.004). IRAP was used to calculate the attribution risk of mortality risk. After multivariable adjustment, patient-related factors including tumor accounted for 90.02% [95% confidence interval (CI), 73.43-96.84%) and physician factors accounted for 17.66% (95% CI, 5.39-44.65%) of the mortalityrisk. All related factors, including patient-related factors and physician factors accounted for 92.02% (95% CI, 77.83-97.43%). Our study demonstrated obvious differences in the prognosis of patients treated by various clinical radiation oncologists. The largest share of prognosis risk was found to be at the patient level, while variation in prognosis was, in part, attributable to differences among physicians.

Sections du résumé

BACKGROUND
To assess the relationship between the level of clinical radiation oncologist and the prognosis of patients with nasopharyngeal carcinoma (NPC). To our knowledge, no previous study has explicitly assessed the relationship with cancer prognosis and clinical radiation oncologists level. The effect of physicians on the prognosis has been entirely ignored.
METHODS
Clinical data were collected for 1140 patients with newly diagnosed NPC. Based on the 3-year overall survival, the treating physicians were classified into 3 grades: high-level group, medium-level group, and low-level group. Cox proportional hazards regression analysis was used to assess the independent significance of different prognostic factors. Propensity score matching (PSM) was used to minimize the influence of confounders so that difference in outcomes provides an unbiased estimate of the influence of physician. Interactive Risk Attributable Program (IRAP) was used to calculate the attribution risk of individual risk factors or a combination of multiple factors.
RESULTS
The 3-year OS in the high-level, medium-level, and low-level groups was 92.9%, 87.7%, and 83.5%, respectively (p = 0.003). After propensity score matching, the 3-year OS was 92.4%, 87.4%, and 82.9%, respectively (p = 0.004). IRAP was used to calculate the attribution risk of mortality risk. After multivariable adjustment, patient-related factors including tumor accounted for 90.02% [95% confidence interval (CI), 73.43-96.84%) and physician factors accounted for 17.66% (95% CI, 5.39-44.65%) of the mortalityrisk. All related factors, including patient-related factors and physician factors accounted for 92.02% (95% CI, 77.83-97.43%).
CONCLUSION
Our study demonstrated obvious differences in the prognosis of patients treated by various clinical radiation oncologists. The largest share of prognosis risk was found to be at the patient level, while variation in prognosis was, in part, attributable to differences among physicians.

Identifiants

pubmed: 32294606
pii: S0167-8140(20)30165-1
doi: 10.1016/j.radonc.2020.03.031
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-135

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Zhaodong Fei (Z)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Xiufang Qiu (X)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Yi Li (Y)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Yingying Huang (Y)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Mengying Li (M)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Taojun Chen (T)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Li Li (L)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Chaoxiong Huang (C)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Jing Liu (J)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Xiang Lin (X)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Bingyi Wang (B)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Yu Chen (Y)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.

Chuanben Chen (C)

Department of Radiotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China. Electronic address: ccbben@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH